Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

339 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.
Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, Gisselbrecht C, Moretti L, Colombat P, Luminari S, Fabbiano F, Di Renzo N, Goldstone A, Carella AM; EBMT/GISL/ANZLG/SFGM/GELA Intergroup HD01 Trial. Federico M, et al. Among authors: carella am. J Clin Oncol. 2003 Jun 15;21(12):2320-5. doi: 10.1200/JCO.2003.11.103. J Clin Oncol. 2003. PMID: 12805333 Clinical Trial.
Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission. Report of the Non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG).
Santini G, Coser P, Chisesi T, Porcellini A, Sertoli R, Contu A, Vinante O, Congiu AM, Carella AM, D'Amico T, et al. Santini G, et al. Among authors: carella am. Ann Oncol. 1991 Feb;2 Suppl 2:181-5. doi: 10.1007/978-1-4899-7305-4_29. Ann Oncol. 1991. PMID: 2049316 Free article. Clinical Trial.
Preliminary analysis of clinical characteristics of patients enrolled in the HD01 protocol: a randomised trial of high dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's disease responding to first line therapy.
Federico M, Clo V, Carella AM. Federico M, et al. Among authors: carella am. Leuk Lymphoma. 1995;15 Suppl 1:63-6. doi: 10.3109/10428199509052710. Leuk Lymphoma. 1995. PMID: 7767264 Clinical Trial. No abstract available.
Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy.
Carella AM, Prencipe E, Pungolino E, Lerma E, Frassoni F, Rossi E, Giordano D, Occhini D, Gatti AM, Bruni R, Spriano M, Nati S, Pierluigi D, Congiu M, Vimercati R, Ravetti JL, Federico M. Carella AM, et al. Leuk Lymphoma. 1996 Mar;21(1-2):63-70. doi: 10.3109/10428199609067581. Leuk Lymphoma. 1996. PMID: 8907271 Clinical Trial.
High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party.
Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Della Volpe A, Linch DC, Schmitz N, Goldstone AH. Sweetenham JW, et al. Among authors: carella am. J Clin Oncol. 1999 Oct;17(10):3101-9. doi: 10.1200/JCO.1999.17.10.3101. J Clin Oncol. 1999. PMID: 10506605
339 results